A relevant animal model is critical for investigating the pathogenic mechanisms underlying hepatitis B virus (HBV)-induced hepatocellular carcinoma (HCC). Mice are not naturally infected by HBV, presumably due to the lack of HBV receptors on mouse hepatocytes. To bypass this entry step of HBV infection, we report generation of a novel HBV model in immunocompetent mice by hepatic delivery of the HBV genome using trans-splicing adeno-associated viral vectors (AAV/HBV). We confirmed production of HBV virions and proteins in the liver and circulation in all AAV/ HBV-transduced mice in all four immunocompetent mouse strains tested. These mice produced antigen and antibody profiles similar to that observed in chronic HBV patients. Importantly, 12-16 months later, all 12 AAV/HBV-transduced mice developed macroscopically visible liver-tumor nodules. Ten of the twelve tumors were characterized with typical HCC features. This AAV/HBV-transduced murine HCC model provides a useful instrument for studying the pathogenesis of HBV-associated HCC and the development of HCC therapeutic interventions.
Introduction
Hepatitis B virus (HBV) chronically infects 400 million people worldwide and leads to a high incidence of severe liver complications, including cirrhosis and hepatocellular carcinoma (HCC), in these patients (1, 2) . HCC is a leading cause of death worldwide and is one of the most difficult cancers to treat (3, 4) , only a small number of patients qualify for curative therapies. The mechanisms responsible for HCC development in chronic HBV patients are not completely understood. Evidence suggests that both the direct viral effect, such as the integration of HBV DNA into host chromosome (5, 6 ) and the transcriptional activity of HBx protein (7) , and the indirect effect of host immune-mediated inflammation and regeneration cycle (8, 9) might be involved in HBV-associated hepatocarcinogenesis. However, progress in understanding the pathogenic mechanisms of HBV-associated HCC has been hampered by the lack of a convenient small animal model.
Chimpanzees are susceptible to HBV infection, but only develop a mild liver inflammatory reaction (10) , and their use in laboratory research is further limited because of ethical and financial considerations. Studies of HBV-related viruses in woodchucks, ground squirrels and ducks have improved our knowledge of HBV virology and the development of antiviral agents, but have not led to a better understanding of HBV immunopathology (11) . Similarly, HBV transgenic mice produce infectious HBV from the chromosome-integrated viral genome, but are centrally tolerant to viral antigens and do not develop liver diseases (12) . A refinement of this latter system, involving the injection of immunocompetent mice with a plasmid containing a full-length HBV genome, resulted in transient (13) or long-term (14) HBV replication in the liver, but caused only limited hepatitis. Adoptive transfer of unprimed splenocytes into HBV transgenic mice on a severe combined immunodeficiency background generated chronic hepatitis with fluctuations in alanine aminotransferase (ALT) levels (15) , but the liver disease was mild and did not progress to HCC, possibly due to the lack of regeneration of HBV-specific T cells in the host.
Here, we report the successful transduction and expression of HBV in the liver of immunocompetent mice using the hepatotropic adeno-associated virus serotype 8 (AAV8) vectors A murine model of hepatitis B-associated hepatocellular carcinoma generated by adeno-associated virus-mediated gene delivery (16) . There are several advantages of using AAV as a vehicle for the delivery of the HBV genome. First, the recombinant AAV vector is defective and contains a genome mostly composed of HBV DNA with only two AAV inverted terminal repeat (ITR) sequences flanking both ends (17) . After binding and entry into hepatocytes (18) , the AAV/HBV vectors produce only HBV but not AAV virions and proteins. Second, in transduced cells the AAV DNA genome is slowly converted to large multimers (or concatamers), mainly in a head-to-tail orientation, through ITR recombination (19) . The AAV concatamer DNA, like HBV covalently closed circular DNA, is episomally maintained and serves as the template for persistent transgene expression. Third, both AAV and HBV are poorly detected by the host innate immune system (20) (21) (22) (23) , favoring their longterm persistence in target cells. We demonstrate that mice transduced with AAV/HBV vectors showed persistent HBV DNA and protein expression. Importantly, we observed HCC development in AAV/HBV-transduced mice. We suggest that this AAV/HBV-induced HCC model will be a useful tool for studying the pathogenic mechanisms of HBV-associated HCC and development of HCC therapeutic drugs.
Materials and methods
Construction and production of AAV vectors. Plasmid pHBV1.3 (24) (Fig. 1A) , containing the 1.3-times overlength HBV genome (genotype D), was split at the CAG/G site between nucleotides 1359 and 1360 (the start codon of core gene was defined as 1), and a highly conserved synthetic intron (25) inserted by PCR. The primer pairs for the 5'-HBV donor fragment (2214 bp) and 3'-HBV acceptor fragment (1976 bp) were 5'-AAAAAGCTT ATGTATTCAATCTAAGCAG-3'; 5'-TTTCTCGAGTAT TGGTCTCCTTAAACCTGTCTTGTAACCTTGATACTT ACCTGAACTGGAGCCACCAGC-3' and 5'-AAAGAA TTCCTCTTGCGTTTCTGATAGGCACCTATTGGTCTT ACTGACATCCACTTTGCCTTTCTCTCCACAGGAACA GTAAACCCTGTTCTG-3'; 5'-TTTGTCGACTACTGAA GGAAAGAAGTCAG-3'. The reverse primer for the donor HBV fragment contains the intronic donor sequence from the first intron in the human β-globulin gene, while the forward primer for the acceptor HBV fragment contains the intronic acceptor sequences from the human immunoglobulin heavy chain gene. These two PCR products were subcloned into the pAAV-MCS vector (Stratagene, La Jolla, CA), which contains the ITR of AAV serotype 2 at both ends, to generate plasmids pAAV5'-HBV-SD and pAAV-3'-HBV-SA. The pAAV-GFP plasmid expressing GFP was a gift from Dr Jin-Jer Cheng (Academia Sinica, Taipei, Taiwan). Pseudotyped AAV8 vectors carrying the 5'-HBV-SD, 3'-HBV-SA, or GFP coding sequence were generated by the triple transfection method and purified by CsCl sedimentation (17) . The physical vector titers were assessed by quantitative PCR (26). Animals. All experimental procedures were reviewed and approved by the Academia Sinica IACUS which is based on Council of Agriculture Guidebook for the Care and Use of Laboratory Animals. The BALB/c, C57BL/6 and FVB mice were purchased from the National Laboratory Animal Breeding and Research Center (Taipei, Taiwan). The ICR mice were purchased from BioLASCO (Ilan, Taiwan). All animals were housed in a specific pathogen-free environment in the animal facilities of the Institute of Biomedical Sciences, Academia Sinica.
AAV injections. All mice were injected i.v. at 6-8 weeks of age with the indicated titer of AAV/5'-HBV-SD, AAV/3'-HBV-SA, or both AAV/5'-HBV-SD and AAV/3'-HBV-SA (AAV/HBV). Mice injected with AAV/GFP were used as negative controls. Sera and tissue samples were collected at different times post AAV injection.
PCR. For quantification of the reconstituted HBV genome, serum HBV DNA was extracted using the QuickGene-810 automated nucleic acid isolation system (Fujifilm, Japan) and quantified by a sensitive hybridization probe-based real-time PCR. The PCR primer pairs for HBV DNA were 5'-CTCCA CCAATCGCCAGTC-3' which was near the end of 5' half of HBV genome and 5'-ATCCTCGAGAAGATTGACGATAAT-3' which was near the head of 3' half of HBV genome. The 3'-fluorescein labeled donor and 5'-Red640-labeled acceptor probes were 5'-CATGGCCTGAGGATGAGTGTTTCTCA-3' and 5'-AGGTGGAGACAGCGGGGTAGG-3' (LightCycler FastStart, Roche Diagnostics, Mannheim, Germany). Plasmid pHBV1.3 was prepared at 10-fold dilutions (1.33x10 3 -1.33x10 9 copies/ml) to generate a standard curve in parallel PCR reactions.
Serological analysis. Sera samples were collected at different times post AAV injection. Serological markers for HBV (HBs, HBe, anti-HBs, anti-HBe and anti-HBc) were quantified using an Elecsys Systems electrochemiluminescence kit and a Cobas e analyzer (Roche Diagnostics GmbH, Mannheim, Germany).
Electron microscopy. Particles in serum samples were concentrated on a 10% sucrose gradient by ultracentrifugation at 287,730 x g at 4˚C for 12 h. The concentrated pellet was resuspended in 50 mM Tris-150 mM NaCl, pH 7.4 buffer, negatively stained with 2% uranyl acetate on a carbon-coated grid, and examined by transmission electron microscopy using a Tecnai G2 Spirit TWIN (FEI Company, Hillsboro, OR) operating at 75 kV.
Histology and immunohistochemistry.
Formaldehyde-fixed and paraffin-embedded liver tissues were sectioned at 5 µm, mounted, heat-fixed onto glass slides, and subjected to hematoxylin-eosin (H&E) staining for general histological inspection, and Sirius Red staining for collagen fiber analysis. For immunohistochemical staining, tissue sections were deparaffinized, soaked in target retrieval solution (TRS, pH 6.1, Dako), and irradiated (500 W) in a microwave oven for 15 min. The tissue sections were then treated with 3% hydrogen peroxide to block any endogenous peroxidase, and blocked with M.O.M. mouse immunoglobulin blocking reagent (Vector Laboratories, Burlingame, CA). The primary antibodies used were mouse anti-HBs (clone 3E7), rabbit antiHBc, and rabbit anti-fibrinogen (all from Dako, Carpinteria, CA). The sections were then washed and incubated with the corresponding horseradish peroxidase-conjugated secondary antibodies. After thorough washing, the sections were immersed in 3,3'-diaminobenzidine (DAB, Sigma-Aldrich, St. Louis, MO) or 3-amino-9-ethylcarbazo (AEC, Sigma-Aldrich) and counterstained with hematoxylin.
Statistical analysis. All data were analyzed for significance by the Student's t-test. p<0.05 was considered significant.
Results

Construction of trans-splicing AAV vectors.
Since mouse hepatocytes are known to support HBV replication (27) , the failure of HBV infection in mice is presumed to be due to the absence of HBV receptors on mouse hepatocytes. To bypass this entry step of HBV infection, we used the hepatotropic AAV serotype 8 vector (AAV8) (16) to introduce the HBV genome into mouse hepatocytes. To fulfill safety requirements of our institute, we employed the AAV trans-splicing technique (25, 28) to generate two independent AAV vectors, AAV/5'-HBV-SD and AAV/3'-HBV-SA, each carrying approximately half of the HBV genome flanked by donor or acceptor splice sequences ( Fig. 1A and B) . We hypothesized that coadministration of these two vectors would generate functional HBV pregenomic and messenger RNAs after head-to-tail intermolecular concatamerization and productive transcription and splicing of the reconstituted HBV genome.
HBV production by trans-splicing AAV vectors. Male BALB/c mice (6-to 8-weeks-old) co-injected intravenously (i.v.) with equal amounts of AAV/5'-HBV-SD and AAV/3'-HBV-SA (denoted hereafter AAV/HBV) ranging from 10 10 to 3x10 12 vector genomes (vg) of each vector per mouse (5 mice per dose) produced HBV DNA in the serum in a dose-dependent manner (Fig. 1C) . Two PCR primers, one annealing to the 5'-half HBV genome and the other to the 3'-half HBV genome, were designed to amplify only the recombined HBV genome. The PCR product from mice receiving both AAV/5'-HBV-SD and AAV/3'-HBV-SA had an expected size of 218 base pairs similar to that produced in HBV transgenic mice ( Fig. 2A) , and the sequence around the predicted split site (CAG/G) was identical to the expected sequence (Fig. 2B) . Electron microscopy demonstrated the presence of viral particles in the serum with a size and structure similar to infectious HBV Dane particles (Fig. 1D) . In contrast, mice injected with saline or control AAV8 vector expressing green fluorescent protein (AAV/GFP) at the dose of 2x10 12 vg per mouse did not produce detectable HBV DNA in the serum. Immunohistochemical analysis of liver tissues revealed that HBV core (HBc) and envelope (HBs) proteins were expressed in mice injected with the AAV/HBV vectors, but not in mice transduced with AAV/ GFP. By contrast, high GFP expression was observed in the liver of mice receiving AAV/GFP as determined by fluorescence microscopic analysis (Fig. 3) . The data for the 10 12 vg group are shown in Fig. 3 , but similar results were obtained in all groups. A dose of 10 12 vg was used in all subsequent experiments. HBV protein expression was seen in the liver, but not in eight other organs examined (Fig. 4) , reflecting the liver tropism of HBV and AAV8 vectors. Since injection of AAV/5'-HBV-SD alone or AAV/3'-HBV-SA alone did not produce detectable HBV DNA in the circulation (data not shown) and the split site was located within the HBV preS1/S2/S and polymerase open reading frames (Fig. 1A) , our results demonstrate that the head-to-tail intermolecular recombination of the AAV genome occurred in the co-transduced hepatocytes and led to production of fully functional HBV genomes and proteins.
To examine whether host genetic background affects HBV production by AAV-mediated HBV infection, three inbred strains [C57BL/6 (n=10), FVB (n=10) and BALB/c (n=15)] and one outbred strain [ICR (n=10)] of mice were injected i.v. with AAV/HBV. All mice used in this experiment were male. Significantly, all mice became HBV-positive 4 weeks after injection of AAV/HBV (Fig. 1E) . The BALB/c and ICR mice produced higher levels of serum HBV [mean titer 6.1x10 5 and 1.0x10 6 genome copies (gc) per ml, respectively] than the C57BL/6 and FVB mice (mean titer 6.6x10 4 and 1.5x10 5 gc per ml, respectively).
We then examined virological features following AAV/ HBV transduction. C57BL/6 mice were given one i.v. injection of AAV/HBV (n=4) or AAV/GFP (n=4), then serum samples were collected 8 weeks later and tested for HBV-specific antigens and antibodies. Significant amounts of HBs (mean titer 2541 IU/ml) and hepatitis B e antigen (HBe, mean titer 691 U/ ml) were detected in mice transduced with AAV/HBV, but not the control AAV/GFP (Fig. 5) . The AAV/HBV-transduced mice were negative for anti-HBs and anti-HBe antibodies, but positive for anti-HBc antibody (Fig. 5 ). This profile of HBV serological markers in AAV/HBV-transduced mice is similar to that observed in chronic hepatitis B patients (2,29) and was maintained for at least 16 months following AAV/HBV transduction (Table I) .
Hepatocellular carcinoma is induced in AAV/HBV-transduced mice.
We then investigated whether HBV can show persistent expression in immunocompetent hosts, C57BL/6 mice were injected i.v. with AAV/HBV (n=6) or AAV/GFP (n=5) as described above. Throughout the 20-week observation period, the AAV/HBV-transduced mice produced relatively stable 
Abbreviations: ND, not determined; TMTC, too many to count; (-), undetectable.
levels of serum HBV, with a mean titer between 3x10 4 -2x10 5 gc per ml (Fig. 6) .
To investigate whether persistent HBV expression in immunocompetent mice led to development of HCC, C57BL/6 mice (n=12) were injected i.v. with AAV/HBV and their livers were removed at 12-16 months after injection for macroscopic and histopathological analysis. All the AAV/HBV-transduced mice (12 of 12, 100%) developed macroscopically visible liver tumor nodules between 12 and 16 months after AAV/HBV transduction (Table I ). Fig. 7A shows an example of the multiple well-vascularized tumors (mouse IF1123, 13 months after AAV/ HBV transduction). Microscopic examination revealed that these tumors had a distinctive nodule-in-nodule appearance (Fig. 7B) , in which a poorly or moderately differentiated HCC, characterized by a pseudoglandular to thick trabecular pattern (T1 region, Fig. 7C ), developed within a well differentiated HCC (T2 region). Other large tumors (>10 mm in diameter) were also diagnosed as moderately to well differentiated HCC, characterized by a pseudoglandular pattern (Fig. 7D) , increased cellularity and nuclear atypia (Fig. 7E) , the absence of portal tracts (Fig. 7F) , and occasional portal invasion by atypical hepatocytes (Fig. 7G) . Round amphophilic cytoplasmic inclusions were occasionally observed in the tumor areas (Fig. 7H) and showed a strong positive immunoreaction for fibrinogen (Fig. 7H, bottom inset) , similar to the structure of the pale bodies found in some human HCCs (30, 31) . Portal and parenchymal inflammatory infiltrates with focal necrosis of multiple hepatocytes were seen through the adjacent non-tumor liver tissue (Fig. 8A and B) . Pronounced steatosis was a common feature in the non-tumor region (Fig. 8C) which occasionally displayed mild to moderate liver fibrosis (Fig. 8D) . In contrast, none of the AAV/GFP-transduced C57BL/6 mice (0 of 5, 0%) developed detectable liver nodules over the 12-to 16-month observation period (Table I) , and their livers showed no apparent histological changes (data not shown). Most of these AAV/GFP-transduced mice had serum ALT levels within the normal range, with an average titer of 60±24 U/l, while ALT levels in the AAV/HBV-transduced mice of a similar age and bearing HCC were significantly elevated, with an average titer of 265±93 U/l (Table I) .
Discussion
HCC is the third leading cause of cancer mortality worldwide, and chronic HBV infection is one of the major risk factors for development of this cancer (1,2). The molecular mechanisms by which HBV infection leads to hepatocarcinogenesis are not completely understood, but evidence suggests that development of HCC may be related to the direct effect of the transcriptional activity of HBx protein (7) or HBV DNA integration (5,6), as well as an indirect effect through immune-mediated hepatic inflammation, injury and regeneration (8, 9) . It is also possible that a combination of viral and host factors are required for HCC development in chronic HBV patients. Therefore, an animal model that can recapitulate both viral and host features in an immunocompetent background will be a valuable tool to study the pathological aspects of HBV-associated HCC. In transgenic mouse studies, overexpression and accumulation of HBV large envelope proteins (32) or X proteins (33) led to development of HCC. However, the whole HBV genome transgenic mice, producing various levels of viral proteins and virions, did not manifest pathological changes or liver tumor development in several previous studies (12, 15, 34) . One disadvantage of using transgenic animals is their central tolerance to HBV (35, 36) , which might partly explain the lack of liver injury and of HCC development in whole HBV genome transgenic mice, since adoptive transfer of HBV-specific T cells induces a high incidence of HCC in these transgenic mice (37) .
To generate a HBV animal model in immunocompetent mice, we used two trans-splicing AAV8 vectors, AAV/5'-HBV-SD and AAV/3'-HBV-SA, to deliver the entire HBV genome into mouse hepatocytes. Our results show that mice co-injected with both donor and acceptor AAV vectors (AAV/HBV) produced HBV DNA (Fig. 1C and E) and HBV proteins, Figure 6 . Kinetics of serum HBV titers after AAV/HBV transduction. C57BL/6 mice were injected with AAV/HBV (n=6) or AAV/GFP (n=5) as described above, then average serum HBV titers (mean ± SD) were measured over time.
including secreted HBs and HBe in the circulation (Fig. 5) and cellular HBc and HBs in hepatocytes (Fig. 3) . The DNA and protein expression patterns are similar to chronic human HBV infection (2) . PCR analysis and sequencing confirmed that the HBV DNA found in AAV/HBV mice had the same sequence as that of wild-type HBV (Fig. 2) , demonstrating the existence of properly oriented AAV/HBV genomes, which produced functional HBV RNAs as templates for production of HBV DNA genome and proteins.
Significantly, at between 12 and 16 months after AAV/ HBV transduction, all mice developed liver tumor nodules, manifesting pathological features of either dysplasia (17%) or HCC (83%) (Fig. 7 and Table I ). The adjacent non-tumor liver tissue was also histologically abnormal, frequently displaying inflammatory infiltrates, steatosis, and focal necrosis (Fig. 8) . Mild to moderate liver fibrosis was also occasionally observed. In contrast, none of the AAV/GFP-transduced mice on the same C57BL/6 background developed tumor nodules in the liver (Table I) , which remained histologically normal on microscopic analysis.
There are several potential mechanisms which might be involved in HCC development in our AAV/HBV-transduced mice. First, the abundant HBV proteins, persistently expressed in AAV/HBV-transduced mice, might have a direct hepatocarcinogenic effect as that reported in human HCC patients and in transgenic mouse studies (32, 33, 38, 39) . Second, as natural HBV infection in humans and chimpanzees (2, 40) , the host immunemediated inflammation may be another factor responsible for HCC development since our AAV/HBV model is also established in the immunocompetent host. Third, AAV-mediated HBV DNA integration into chromosome of hepatocytes may also contribute to HCC development. AAV vectors have been found to integrate into host cell chromosomes in a non-specific manner, favoring transcriptionally active genes and DNA breakage sites (41, 42) . However, our results (Table I) and those from other studies (43) (44) (45) , including a large-scale study of 695 mice and sequencing of over 1000 integration sites, did not show any increased risk of developing liver tumors or other tumor types in AAV-treated mice. However, there also have been reports that AAV-mediated gene therapy did increase the risk of formation of liver tumors (46, 47) and that this is associated with AAV insertion and overexpression of the Rian gene, containing multiple small nucleolar RNAs, and of the Mirg gene, containing multiple microRNAs. We did not detect increased expression of the Rian and Mirg genes in AAV/ HBV-induced tumors (unpublished results), arguing against a role of these two genes in hepatocarcinogenesis in our HCC model. However, we can not formally rule out the possibility that the inserted HBV gene controlling elements (HBV enhancers and promoters), which are present in our model but not in AAV vectors of other studies, might play a role in liver carcinogenesis of our AAV/HBV-induced HCC model.
Compared to HCC models established in genetically engineered mice involving either overexpression of oncogenic proteins or germline disruption of tumor suppressors (48, 49) , our AAV/HBV-transduced HCC model has the advantages of easy manipulation and recapitulation of both the viral and immune effectors known to be critical in the development of human HBV-associated HCC. This AAV/HBV murine HCC model therefore provides a useful tool for studying the pathogenic mechanisms responsible for HBV-associated HCC and the development of HCC therapeutic drugs.
